Welcome to LookChem.com Sign In|Join Free
  • or


Post Buying Request

183319-69-9 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Erlotinib HCl CAS183319-69-9
Cas No: 183319-69-9
USD $ 2000.0-2000.0 / Kilogram 1 Kilogram 25 Kilogram/Month Jinan Hongfangde Pharmatech Co.,Ltd Contact Supplier
CAS:183319-69-9 Erlotinib hydrochloride
Cas No: 183319-69-9
No Data 1 Kilogram 1000 Kilogram/Month Shaanxi WuZhiYuan Biological Technology Co.,Ltd Contact Supplier
Topsale Erlotinib hydrochloride 99%
Cas No: 183319-69-9
USD $ 100.0-100.0 / Kilogram 1 Kilogram 10000 Metric Ton/Day Shanghai Upbio Tech Co.,Ltd Contact Supplier
Lower price manufacturer 99%Erlotinib hydrochloride
Cas No: 183319-69-9
USD $ 100.0-100.0 / Kilogram 1 Kilogram 10 Metric Ton/Month Taizhou Creating Chemical Co.,Ltd Contact Supplier
white powder price high quality Erlotinib Hydrochloride
Cas No: 183319-69-9
USD $ 280.0-280.0 / Kilogram 1 Kilogram 1 Metric Ton/Day Wuhan Vanz Pharm Inc. Contact Supplier
Erlotinib hydrochloride Manufacturer/High quality/Best price/In stock
Cas No: 183319-69-9
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
Erlotinib hydrochloride CAS NO.183319-69-9
Cas No: 183319-69-9
No Data 1 Kilogram 500~1000 Kilogram/Month Hubei Jusheng Technology Co., Ltd., Contact Supplier
Erlotinib hydrochloride
Cas No: 183319-69-9
USD $ 500.0-500.0 / Gram 1000 Gram 10 Metric Ton/Month Hebei yanxi chemical co.,LTD. Contact Supplier
High purity Various Specifications Erlotinib hydrochloride CAS:183319-69-9
Cas No: 183319-69-9
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
Top quality Erlotinib hydrochloride Cas 183319-69-9 with competitive price
Cas No: 183319-69-9
No Data 100 Gram 200 Kilogram/Month Wuhan Fortuna Chemical Co.,Ltd Contact Supplier

183319-69-9 Usage

Chemical Properties

Off-White Solid


Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Phase 3.


ChEBI: A quinazoline hydrochloride compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.

Mechanisms of Action

The small molecular compound erlotinib is a tyrosine kinase receptor inhibitor which inhibits the proliferation of tumor cells by inhibiting phosphorylation, binding to the intracellular catalytic domain of tyrosine kinase in competition with ATP, thus blocking downstream signal transduction and inhibiting activity of tumor cell ligand dependent HER-1/EGFR.


Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic


Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.

Clinical Research

Phase I clinical trials showed that the main toxicities and side effects of erlotinib were dose-dependent rashes and diarrhea. Other rare side effects included headaches, nausea, and vomiting. Phase II trials used erlotinib as a second-line anticancer drug, with efficacy matching second-line chemotherapy drug docetaxel. Phase III randomized control trials (BR21) mainly focused on NSCLC patients (locally advanced and distant metastasis) after the failure of first- or second-line chemotherapy. The treatment group, with 488 cases in total, took 150mg of erlotinib daily. The control group (243 cases) took a placebo. The study showed:
Median survival rate: 6.7 months for the treatment group, 4.7 months for the control (P<0.001, hazard ratio HR=0.73)
1 year survival rate: 31.2% for the treatment group, 21.5% for the control
Median time of no progression: 9.9 weeks for the treatment group, 7.9 weeks for the control
Meanwhile, symptomatic improvement in the treatment group was more pronounced.
Based on the results of the BR21 study, several further phase III clinical trials were conducted. The TRIBUTE trial combined erlotinib with chemotherapy. The treatment group used chemotherapy (carboplatin + paclitaxel) + erlotinib, while the control used the same chemotherapy alone, with a total of 1,059 late-stage NSCLC patients. The effectiveness of the treatment group was 21.5%, and the control group 19.3%; median survival times were 10.8 and 10.6 months, respectively, and the times of tumor progression (TTP) were 5.1 and 5.0 months. Meanwhile, TALENT trials, with 1,172 NSCLC patients, also investigated the effects of adding erlotinib to chemotherapy (gemcitabine + cisplatin), and also failed to show that erlotinib significantly increased its effects.

Indications and Usage

Erlotinib hydrochlorate is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal growth factor receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer.
It is mainly used as a second- or third-line treatment for locally advanced or metstatic non-small cell lung cancer (NSCLC) and as a treatment for pancreatic cancer. It is used as a tyrosine inhibitor for NSCLC treatment.

Brand name

Tarceva (OSI).



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017


1.1 GHS Product identifier

Product name erlotinib hydrochloride

1.2 Other means of identification

Product number -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:183319-69-9 SDS

183319-69-9Related news

Recrystallization of Erlotinib hydrochloride (cas 183319-69-9) and fulvestrant using supercritical antisolvent process07/12/2019

Recrystallization of two anti-cancer active pharmaceutical ingredients (APIs), erlotinib hydrochloride (erlotinib HCl) and fulvestrant, using supercritical antisolvent (SAS) process was investigated in this study. The most commonly used supercritical carbon dioxide was employed as the antisolven...detailed

Use of roller compaction and fines recycling process in the preparation of Erlotinib hydrochloride (cas 183319-69-9) tablets07/11/2019

This study focuses on improving the manufacturing process for a generic immediate-release tablet containing erlotinib hydrochloride by adding a fines recycling process during roller compaction. Due to the large fraction of small-sized API particles, the starting powder mixture was inconsistently...detailed

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields